Loading...
•
Dec 31, 2020
Celcuity Q4 2020 Earnings Report
Celcuity's financial performance for Q4 2020 and the full year was reported, highlighting collaborations and progress in clinical trials.
Key Takeaways
Celcuity Inc. reported a net loss of $2.55 million for the fourth quarter of 2020, compared to a net loss of $1.81 million for the fourth quarter of 2019. The company's operating expenses were $2.55 million, up from $1.90 million in the same quarter of the previous year. Celcuity had cash and cash equivalents of $11.6 million as of December 31, 2020.
Announced clinical trial collaborations with Massachusetts General Hospital, UCLA, Vanderbilt, Puma Biotechnology, Sarah Cannon Research Institute, and Pfizer Inc.
Total operating expenses were $2.55 million for the fourth quarter of 2020, compared to $1.90 million for the fourth quarter of 2019.
Net loss for the fourth quarter of 2020 was $2.55 million, or $0.25 per share, compared to a net loss of $1.81 million, or $0.18 per share, for the fourth quarter of 2019.
At December 31, 2020, Celcuity had cash and cash equivalents of $11.6 million, compared to cash and cash equivalents of $18.7 million at December 31, 2019.
Forward Guidance
Celcuity anticipates announcing additional clinical trial collaborations in the first half of 2021 and expects interim results from the FACT-1 and FACT-2 trials in late 2021 or early 2022.
Positive Outlook
- Expect to announce additional clinical trial collaborations in the first half of 2021.
- Continue to develop CELsignia RAS test for breast and ovarian cancers, and plan to report data on these new tests in the first half of 2021.
- Interim results from the FACT-1 and FACT-2 trials are expected in late 2021 or early 2022.
Challenges Ahead
- The COVID-19 pandemic has impacted Celcuity's business and results of operations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...